Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology and Market Forecasts, 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pulmonary
Arterial Hypertension (PAH) – Market Insights, Epidemiology and Market
Forecast-2027”
report has been added to ResearchAndMarkets.com’s
offering.

Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology
and Market Forecast – 2027 report delivers an in-depth understanding of
the disease, historical & forecasted epidemiology as well as the market
trends of AC in the United States, EU5 (Germany, Spain, Italy, France
and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs
having the potential to get launched in the forecast period, market
share of the individual therapies, and current and forecasted market
size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027
segmented by seven major markets. The Report also covers current
treatment practice/algorithm, market drivers, market barriers and unmet
medical needs to curate best of the opportunities and assess underlying
potential of the market.

Key Topics Covered:

1. Key Insights

2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance

3. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

4. Epidemiology and Patient Population

5. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

6. Treatment Algorithm

7. Unmet Needs

8. Marketed Drugs

9. Marketed Drugs by Companies

10. Safety and Efficacy of Marketed Drugs

11. Emerging Therapies

12. Global Market Size of Pulmonary Arterial Hypertension (PAH)

13. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis

14. Pulmonary Arterial Hypertension (PAH): Market Outlook by Region

15. United States

16. EU5 Countries

17. Rest of World (ROW)

18. Rest of Europe (ROE)

19. Market Drivers

20. Market Barriers

21. Appendix

22. Capabilities

Companies Mentioned

  • United Therapeutics Corporation
  • Actelion Pharmaceuticals Ltd.
  • GSK
  • Bayer AG
  • Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/prfvwq/pulmonary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs